论文部分内容阅读
应用常规保肝治疗和加用丽珠肠乐两组(对照组和治疗组)共治疗120例。治疗组和对照组比较,结果如下:临床症状总有效率在慢迁肝、慢活肝及肝硬化中P值均<0.01。慢迁肝中ALT复常中P<0.05,肝硬化中ALT下降、SB下降、白蛋白上升及鲎血试验中转阴P值分别为<0.01、<0.01、<0.05和<0.01。本文提示在慢性肝炎、肝硬化常规保肝治疗基础上再加用丽珠肠乐能取得较好疗效,值得推广应用。
120 cases were treated with conventional hepatoprotective therapy plus Livzon Grenadine (control group and treatment group). The treatment group and the control group, the results are as follows: The total effective rate of clinical symptoms in slowly moving liver, slow liver and liver cirrhosis in the P values were <0.01. ALT normalization in slow moving liver P <0.05, decreased ALT in liver cirrhosis, decreased SB, elevated albumin and hematemesis P values were <0.01, <0.01, <0.05 and <0.01. This article suggests that in the treatment of chronic hepatitis and liver cirrhosis with conventional hepatoprotective therapy, Lizhu Changle can achieve better curative effect and is worth popularizing and applying.